Multiple sclerosis

Alan J. Thompson, Sergio E. Baranzini, Jeroen Geurts, Bernhard Hemmer, Olga Ciccarelli

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Multiple sclerosis continues to be a challenging and disabling condition but there is now greater understanding of the underlying genetic and environmental factors that drive the condition, including low vitamin D levels, cigarette smoking, and obesity. Early and accurate diagnosis is crucial and is supported by diagnostic criteria, incorporating imaging and spinal fluid abnormalities for those presenting with a clinically isolated syndrome. Importantly, there is an extensive therapeutic armamentarium, both oral and by infusion, for those with the relapsing remitting form of the disease. Careful consideration is required when choosing the correct treatment, balancing the side-effect profile with efficacy and escalating as clinically appropriate. This move towards more personalised medicine is supported by a clinical guideline published in 2018. Finally, a comprehensive management programme is strongly recommended for all patients with multiple sclerosis, enhancing health-related quality of life through advocating wellness, addressing aggravating factors, and managing comorbidities. The greatest remaining challenge for multiple sclerosis is the development of treatments incorporating neuroprotection and remyelination to treat and ultimately prevent the disabling, progressive forms of the condition.
Original languageEnglish
Pages (from-to)1622-1636
JournalThe Lancet
Volume391
Issue number10130
DOIs
Publication statusPublished - 2018

Cite this

Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018). Multiple sclerosis. The Lancet, 391(10130), 1622-1636. https://doi.org/10.1016/S0140-6736(18)30481-1
Thompson, Alan J. ; Baranzini, Sergio E. ; Geurts, Jeroen ; Hemmer, Bernhard ; Ciccarelli, Olga. / Multiple sclerosis. In: The Lancet. 2018 ; Vol. 391, No. 10130. pp. 1622-1636.
@article{ec14406ea7354295b7006529b3349690,
title = "Multiple sclerosis",
abstract = "Multiple sclerosis continues to be a challenging and disabling condition but there is now greater understanding of the underlying genetic and environmental factors that drive the condition, including low vitamin D levels, cigarette smoking, and obesity. Early and accurate diagnosis is crucial and is supported by diagnostic criteria, incorporating imaging and spinal fluid abnormalities for those presenting with a clinically isolated syndrome. Importantly, there is an extensive therapeutic armamentarium, both oral and by infusion, for those with the relapsing remitting form of the disease. Careful consideration is required when choosing the correct treatment, balancing the side-effect profile with efficacy and escalating as clinically appropriate. This move towards more personalised medicine is supported by a clinical guideline published in 2018. Finally, a comprehensive management programme is strongly recommended for all patients with multiple sclerosis, enhancing health-related quality of life through advocating wellness, addressing aggravating factors, and managing comorbidities. The greatest remaining challenge for multiple sclerosis is the development of treatments incorporating neuroprotection and remyelination to treat and ultimately prevent the disabling, progressive forms of the condition.",
author = "Thompson, {Alan J.} and Baranzini, {Sergio E.} and Jeroen Geurts and Bernhard Hemmer and Olga Ciccarelli",
year = "2018",
doi = "10.1016/S0140-6736(18)30481-1",
language = "English",
volume = "391",
pages = "1622--1636",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10130",

}

Thompson, AJ, Baranzini, SE, Geurts, J, Hemmer, B & Ciccarelli, O 2018, 'Multiple sclerosis' The Lancet, vol. 391, no. 10130, pp. 1622-1636. https://doi.org/10.1016/S0140-6736(18)30481-1

Multiple sclerosis. / Thompson, Alan J.; Baranzini, Sergio E.; Geurts, Jeroen; Hemmer, Bernhard; Ciccarelli, Olga.

In: The Lancet, Vol. 391, No. 10130, 2018, p. 1622-1636.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Multiple sclerosis

AU - Thompson, Alan J.

AU - Baranzini, Sergio E.

AU - Geurts, Jeroen

AU - Hemmer, Bernhard

AU - Ciccarelli, Olga

PY - 2018

Y1 - 2018

N2 - Multiple sclerosis continues to be a challenging and disabling condition but there is now greater understanding of the underlying genetic and environmental factors that drive the condition, including low vitamin D levels, cigarette smoking, and obesity. Early and accurate diagnosis is crucial and is supported by diagnostic criteria, incorporating imaging and spinal fluid abnormalities for those presenting with a clinically isolated syndrome. Importantly, there is an extensive therapeutic armamentarium, both oral and by infusion, for those with the relapsing remitting form of the disease. Careful consideration is required when choosing the correct treatment, balancing the side-effect profile with efficacy and escalating as clinically appropriate. This move towards more personalised medicine is supported by a clinical guideline published in 2018. Finally, a comprehensive management programme is strongly recommended for all patients with multiple sclerosis, enhancing health-related quality of life through advocating wellness, addressing aggravating factors, and managing comorbidities. The greatest remaining challenge for multiple sclerosis is the development of treatments incorporating neuroprotection and remyelination to treat and ultimately prevent the disabling, progressive forms of the condition.

AB - Multiple sclerosis continues to be a challenging and disabling condition but there is now greater understanding of the underlying genetic and environmental factors that drive the condition, including low vitamin D levels, cigarette smoking, and obesity. Early and accurate diagnosis is crucial and is supported by diagnostic criteria, incorporating imaging and spinal fluid abnormalities for those presenting with a clinically isolated syndrome. Importantly, there is an extensive therapeutic armamentarium, both oral and by infusion, for those with the relapsing remitting form of the disease. Careful consideration is required when choosing the correct treatment, balancing the side-effect profile with efficacy and escalating as clinically appropriate. This move towards more personalised medicine is supported by a clinical guideline published in 2018. Finally, a comprehensive management programme is strongly recommended for all patients with multiple sclerosis, enhancing health-related quality of life through advocating wellness, addressing aggravating factors, and managing comorbidities. The greatest remaining challenge for multiple sclerosis is the development of treatments incorporating neuroprotection and remyelination to treat and ultimately prevent the disabling, progressive forms of the condition.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044296592&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29576504

U2 - 10.1016/S0140-6736(18)30481-1

DO - 10.1016/S0140-6736(18)30481-1

M3 - Review article

VL - 391

SP - 1622

EP - 1636

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 10130

ER -

Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. The Lancet. 2018;391(10130):1622-1636. https://doi.org/10.1016/S0140-6736(18)30481-1